Aims The aim of this study was to compare the effects of aspirin on platelet function as measured by the 'classical' template bleeding time with a new ex vivo method measuring closure times using the PFA-100@ machine. Platelet aggregation in response to arachidonic acid was also measured ex vivo. Methods The trial was a randomized, double-blind, placebo-controlled crossover design, with each volunteer taking 750 mg aspirin (BP) or placebo, three times a day for 5 days, with an 18 day wash-out period between treatments. Bleeding times and closure times were measured before the first dose on the first day and 0.5 h after the last dose on the fifth day of each treatment period. They were also measured 2 weeks after the last day of the trial. Results Baseline bleeding times ( pre-placebo) were 415 s using the Simplate, whilst baseline closure times were 115 s using the PFA-100@. Aspirin treatment caused an increase of both the template bleeding time (61%) and the closure time of the PFA-100@ (79%) when compared with the effects of placebo. The platelet aggregatory response to arachidonic acid was completely inhibited following aspirin treatment and was unaffected following placebo. Two weeks after the end of the trial, all values had returned to pre-treatment levels. The template bleeding time was unaltered in 1 of the 12 volunteers during aspirin treatment and was significantly prolonged in 3 of the 12 volunteers during placebo treatment. The PFA-100@ closure time was unaltered in 1 of the 12 volunteers during aspirin treatment and was prolonged in 1 subject during placebo treatment. Conclusions The change in closure time using the PFA-100@ is as sensitive and reproducible to the effects of aspirin on platelet function as is the template bleeding time test. However, the PFA-100@ produced less variable effects with fewer false positive results.
Introduction Furthermore, they involve an invasive procedure which produces scarring of varying degrees. Measurement of the consequence of platelet dysfunction or of the effects of drug treatment on the normal haemostatic The bleeding time is determined by the formation of a platelet plug at the site of injury. Drugs and diseases that mechanism in patients and volunteers has been the subject of much experimentation over many decades. All techniques affect platelet aggregation prolong bleeding time, whereas factors affecting coagulation of blood, such as haemophilia, have involved some form of cutaneous incision and an estimation of the time taken for the bleeding to cease. The do not. Recently, an automated method (PFA-100@) has been described [8, 9] which, it is suggested, can be used to original method of Duke [1] was changed from the ear-lobe to the forearm by Ivy [2] , and was then standardized with evaluate the effects of platelet disorders and drugs on platelet function by making an ex vivo measurement based upon the the introduction into routine practice of the Simplate@ device, which produced a uniform size of cut by virtue of formation of a platelet plug. This device requires only a small sample of venous blood to be taken from the subject a spring-loaded blade [3] .
Such techniques have been regularly used to help diagnose into an anticoagulant. The sample is then placed into the PFA-100@ where it is drawn through a capillary tube and platelet dysfunction or disorders [4, 5] , as well as to evaluate the effects of drugs which may attenuate haemostasis in the comes into contact with a membrane. This membrane is coated with collagen and (in the present experiments) treatment of, for example, unstable angina [6, 7] . Whilst such methods are capable of detecting such activity, they adrenaline to activate the platelets. The blood is then aspirated through a precision aperture (147 mm diameter) in the membrane and platelets begin to adhere to the circumference of the aperture. A stable platelet plug then forms that occludes the aperture and the time taken for placed into the PFA-100 analyser for measurement of the closure time. The cartridges used were collagen/adrenaline, blood to stop passing through the aperture is registered. This time is described as the closure time and is an ex vivo as these are reported to be sensitive to the platelet-inhibitory effects of aspirin [8] . Each blood sample was tested in assessment of platelet function. The purpose of the present study was to compare platelet function in healthy, male duplicate and the mean closure time calculated. A further 20 ml blood sample was taken into a 50 ml volunteers by measuring bleeding time using the Simplate method and closure times using the PFA-100, and to assess syringe containing 2 ml of 3.2% (w/v) trisodium citrate. Platelet-rich plasma (PRP) was prepared by centrifugation the effects of aspirin or placebo treatment on these values. To confirm the effects of aspirin on platelet function, we at 200 g for 15 min (25°C) and 0.25 ml aliquots dispensed into siliconised glass tubes. These were stirred at also evaluated the effects of treatment on platelet aggregation, ex vivo, using arachidonic acid to stimulate aggregation of 900 rev min −1 and pre-incubated at 37°C for 60 s in a Biodata aggregometer. Aggregation was stimulated by the platelet-rich plasma.
addition of arachidonic acid and measured as an increase of light transmission (minimum and maximum transmission Methods having been set previously using PRP and platelet-poor plasma, respectively). Each aggregation response was allowed Subjects to proceed to its maximum and the EC 50 from a full concentration-response curve calculated. Twelve, healthy, male volunteers (age range 27-50 years) were recruited from the Zeneca Pharmaceuticals Volunteer
The volunteers were required to take their treatment at 08.00, 16.00 and 24.00 h each day, with normal food intake. panel to take part in this trial. Health was confirmed on the basis of a normal medical, which included history and On the fifth day, volunteers were required to take their last treatment (08.00 h) and then a repeat of the bleeding time, examination, clinical chemistry, haematology and urinalysis, respiratory function tests (FEV 1 and FVC), 12-lead ECG closure time and platelet aggregation measurements were made 0.5 h after the final dose of aspirin or placebo. and 24 h ambulatory cardiac monitoring. A negative test for hepatitis B surface antigen was also a pre-requisite for this After 18 days, each volunteer returned and the process was repeated with the alternate drug treatment. study. Volunteers were required to abstain from the use of any aspirin-like drugs for 14 days prior to the first study day Two weeks after the last treatment day, all volunteers received a post-trial medical examination and a final and throughout the duration of the study.
All volunteers gave fully informed written consent prior assessment of the bleeding time and closure time. to participation in the study, which was approved by the independent Zeneca Pharmaceuticals Research Ethics Drug supply Committee.
Aspirin was supplied as aspirin BP, 300 mg, from Unichem. The placebo tablets were provided by the Pharmaceutical
Study design
Department of Zeneca Pharmaceuticals.
This was a double-blind, placebo-controlled cross-over study with the volunteers being randomly assigned to take either Data analysis 750 mg aspirin, three times per day for 5 days, or matching The data were analysed by analysis of variance, the treatment placebo. There was an 18-day washout period between the effect being estimated from the difference between the two arms of the study and the volunteers also received a placebo and the aspirin least squares means. The existence post-trial medical examination 14 days after the end of the of differential carry-over was assessed by fitting an analysis dosing period.
of covariance model to the pre-dose value in the second On the first study day, the volunteers were required to period of the crossover, allowing for the baseline in the remain supine for 30 min, prior to a measurement of first period and a treatment sequence effect. bleeding time using the Simplate technique [3] . Briefly, a
To assess the reproducibility of each measurement within blood pressure cuff was placed around the upper arm and a volunteer, the lowest and highest values of bleeding time inflated to 40 mm Hg. An area on the volar surface of the and closure time were compared using both pre-dose periods forearm was swabbed with alcohol and allowed to air dry.
and the values at the post-trial medical (i.e the three base-A single incision was made in line with the forearm with line assessments). The differences between these values the Simplate device and the blood blotted with a filter paper within each individual were expressed as a percent difference. every 30 s until bleeding had stopped. Care was taken during the blotting not to touch the edge of the clot and Results wound, and the same individual conducted all the bleeding time measurements throughout the study. The time taken
All volunteers completed the trial successfully with only from the incision being made to the end of bleeding was minor adverse events reported. An analysis of covariance measured. The same operator made the bleeding time showed there was no carryover between treatments. measurements in the same volunteer throughout the trial period. From a 16g cannula inserted into an antecubital
Simplate method vein on the other arm, a 2 ml blood sample was drawn and gently expelled into a citrate-coated tube, capped and Before aspirin treatment, the mean bleeding time was 443 s (range=270-870), whilst on the placebo arm of the trial, inverted to ensure mixing. An 800 ml sample of this was the mean closure time was 117 s (range=87-144, Figure 1 ). The mean difference between the two baseline and posttrial measurements of closure time was 21%. In one volunteer, the closure time did not increase following either treatment period and in another volunteer it increased by a similar time following both treatments (29 s following aspirin and 24 s following placebo. Figure 2) . In three volunteers, the blood sample ran out before registering a closure time following aspirin treatment.
Platelet aggregation
Aspirin treatment abolished the aggregatory response to arachidonic acid in all 12 volunteers, such that the mean pre-aspirin EC 50 was 337 mm (range=146-690) whilst postaspirin, no aggregation was observed following the highest concentration used (2 mm). The mean EC 50 pre-placebo was 310 mm (range=155-632) and post-placebo was 362 mm (range=142-689).
Discussion
The purpose of the present study was to compare platelet function by measuring the bleeding times using the standard template method (Simplate device) with the closure times obtained using a new machine, the PFA-100@, and to determine the effects of aspirin on these times in a placebo controlled, cross-over study in healthy, male volunteers.
In our volunteers, the template bleeding times using the Simplate device were within the ranges previously described haemostatic response of that individual and, as part of a haematological examination, would warrant further detailed examination of that individual's platelet function. In the the pre-dose value was 415 s (range=300-660). Following 5 days treatment with aspirin, the bleeding time rose to present trial, however, there was no consistency in the bleeding times which were outside the normal range; thus, a mean of 855 s (range=480-2190), the corresponding bleeding time after placebo being 530 s (range=330-1740).
at the post-trial medical all the bleeding times were very close, suggesting that the very long bleeding times in the The effect of aspirin was highly significant when compared against placebo (P=0.001), the increase being 61%. At the post-dose placebo and the post-dose aspirin groups were, indeed, 'outliers' rather than individuals with an intrinsic post-trial medical, the mean bleeding time was 418 s (range=270-600. Figure 1) . The mean difference between clotting deficiency. Overall, however, this method has demonstrated the known effects of aspirin treatment to the two base-line and post-trial measurements of bleeding time was 47%. In three of the volunteers, bleeding time prolong bleeding time, in the present case by 61% when compared with the effect of placebo. increased by a similar time following both aspirin and placebo treatment, whilst a fourth volunteer did not show
The PFA-100@ is a newly-available machine which has been developed from the Thrombostat 4000, originally an increase of bleeding time following either treatment (Figure 2) .
developed by Kratzer & Born [11] . The Thrombostat was evaluated in a number of studies and shown to be at least as sensitive to the effects of aspirin on bleeding time compared Closure time, PFA-100 method with both the Simplate [12] and a lancet [13] method. However, its widespread use was hampered by problems of Before aspirin treatment, the mean closure time was 123 s (range=83-161) and prior to placebo was 115 s (range= reproducibility in the preparation of the collagen-coated filters used. The PFA-100@ has overcome these difficulties 88-134). Following treatment with aspirin, the mean closure time increased to 217 s (range=120-300) whilst after and has also made use of more modern micro-chip technology to faciltate user-friendliness. In our experience, placebo it was 122 s (range=76-152). The effect of aspirin was highly significant when compared with placebo ( P= the PFA-100@ was quick and simple to use and very robust. Preliminary tests confirmed the reported difference in 0.001), the increase being 79%. At the post-trial medical, closure times seen between the two sample wells available one subject, bleeding time was increased by 22 min following aspirin and 18 min following placebo. However, at the post- [9] and we chose to use just the first well and repeat the samples twice. However, further evaluation during the trial examination, both methods produced a similar range of values to the two pre-dose times, with no significant course of the present study suggested that this did not provide any advantage over the recommended method of outliers. Thus, the PFA-100 appears to be less prone to produce false positive results than the Simplate method. testing in duplicate using the two wells provided.
The normal range of closure times obtained in our Whilst both methods have demonstrated the known effects of aspirin on the normal haemostatic mechanism in volunteers corresponds well with those reported from other trials, the range of pre-drug values being between 83 and healthy male volunteers, the PFA-100@ is not necessarily a direct replacement for the Simplate bleeding time. Rather, 161 s in the present study and from 77-133 s in the study by Mammen et al. [9] . The PFA-100 values were also less it can be used as a technique to provide rapid information on global platelet function and, in this respect, it offers variable than the bleeding time values, with coefficients of variation of 12% for the PFA-100 and 23% for the Simplate distinct advantages over the Simplate method. The closure times are objective and less variable and, of particular method. The increase of closure time following aspirin treatment was 79% when compared with the placebo effect, concern when evaluating the effects of drugs on haemostasis, it requires only a venous blood sample to be provided, thus using the PFA-100@, a similar value to that obtained with the Simplate device (61%). Thus, both methods appear eliminating the need for an incision to be made to the subject. equally capable of detecting the effect of aspirin on platelet plugging.
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